The insufficient blood flow and oxygen supply in solid tumor cause hypoxia, which leads to low sensitivity of tumorous cells and thus causing poor treatment outcome. Here, mesoporous manganese dioxide (mMnO 2 ) with ultrasensitive biodegradability in a tumor microenvironment (TME) is grown on upconversion photodynamic nanoparticles for not only TME-enhanced bioimaging and drug release, but also for relieving tumor hypoxia, thereby markedly improving photodynamic therapy (PDT). In this nanoplatform, mesoporous silica coated upconversion nanoparticles (UCNPs@mSiO 2 ) with covalently loaded chlorin e6 are obtained as near-infrared light mediated PDT agents, and then a mMnO 2 shell is grown via a facile ultrasonic way. Because of its unique mesoporous structure, the obtained nanoplatform postmodified with polyethylene glycol can load the chemotherapeutic drug of doxorubicin (DOX). When used for antitumor application, the mMnO 2 degrades rapidly within the TME, releasing Mn 2+ ions, which couple with trimodal (upconversion luminescence, computed tomography (CT), and magnetic resonance imaging) imaging of UCNPs to perform a selfenhanced imaging. Significantly, the degradation of mMnO 2 shell brings an efficient DOX release, and relieve tumor hypoxia by simultaneously inducing decomposition of tumor endogenous H 2 O 2 and reduction of glutathione, thus achieving a highly potent chemo-photodynamic therapy.

Abstract. Early-season crop identification is of great importance for monitoring crop growth and predicting yield for decision makers and private sectors. As one of the largest producers of winter wheat worldwide, China outputs more than 18 % of the global production of winter wheat. However, there are no distribution maps of winter wheat over a large spatial extent with high spatial resolution. In this study, we applied a phenology-based approach to distinguish winter wheat from other crops by comparing the similarity of the seasonal changes of satellite-based vegetation index over all croplands with a standard seasonal change derived from known winter wheat fields. Especially, this study examined the potential of early-season large-area mapping of winter wheat and developed accurate winter wheat maps with 30 m spatial resolution for 3 years (2016–2018) over 11 provinces, which produce more than 98 % of the winter wheat in China. A comprehensive assessment based on survey samples revealed producer's and user's accuracies higher than 89.30 % and 90.59 %, respectively. The estimated winter wheat area exhibited good correlations with the agricultural statistical area data at the municipal and county levels. In addition, the earliest identifiable time of the geographical location of winter wheat was achieved by the end of March, giving a lead time of approximately 3 months before harvest, and the optimal identifiable time of winter wheat was at the end of April with an overall accuracy of 89.88 %. These results are expected to aid in the timely monitoring of crop growth. The 30 m winter wheat maps in China are available via an open-data repository (DOI: https://doi.org/10.6084/m9.figshare.12003990, Dong et al., 2020a).

Background The clinical utility of malignant pleural effusion (MPE) to detect mutation has been well documented; however, routine practice of the use of MPE involves collection of the cell pellet to detect mutation, and limited studies have interrogated the MPE supernatant as an alternative source of tumor‐derived DNA for mutation profiling. In this study, we investigated the potential of MPE supernatant as a liquid biopsy specimen by comparing its mutation profile with that of matched MPE cell pellets, tissue, and plasma samples. Methods Sequencing data from 17 patients with matched lung tissue, plasma, and MPE samples were retrospectively analyzed. Capture‐based targeted sequencing was performed on matched plasma and MPE supernatant samples obtained from 154 patients with advanced lung adenocarcinoma. Results MPE supernatants had significantly higher median maximum allelic fractions (maxAFs) than their corresponding cell pellets ( P = 0.008) and plasma samples ( P = 0.036), and a comparable maxAF value to that of tissue samples ( P = 0.675). Comparison of MPE supernatant and matched plasma samples from the larger cohort ( n = 154) revealed a comparable mutation detection rate; however, MPE supernatant had a significantly higher median maxAF than plasma (20.3% vs. 1.13%; P < 0.001). Furthermore, the concordance rates between MPE supernatant and plasma for single‐nucleotide and copy number variations were 56% and 18%, respectively, suggesting that MPE supernatant reveals a more comprehensive mutation spectrum, particularly for copy number variations. Conclusion Overall, our study shows that MPE supernatant is an optimal alternative source of tumor‐derived DNA for comprehensive mutation profiling.

Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5–10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.

A yolk-like nanocapsule with responsiveness to tumor microenvironment and NIR photons was invented by integrating a tumor-responsive photothermal agent on Mn-doped UCNPs@mSiO2 nanospheres for multiple imaging guided thermo-chemotherapy.